Jingfukang induces anti-cancer activity through oxidative stress-mediated DNA damage in circulating human lung cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Jingfukang induces anti-cancer activity through oxidative stress-mediated DNA damage in circulating human lung cancer cells

Published:2019-08-07 Issue:1 Volume:19 Page:
ISSN:1472-6882
Container-title:BMC Complementary and Alternative Medicine
language:en
Short-container-title:BMC Complement Altern Med

Author:

Que Zujun,Zhou Zhiyi,Luo Bin,Dong Changsheng,Jiang Yi,Li Hegen,Tian Jianhui

Funder

National Natural Science Foundation of China

Clinical Science and technology innovation project of Shanghai Shenkang Hospital Development Center

Excellent Academic Leaders of Health and Family Planning System in Shanghai

Sponsored by Shanghai Sailing Program

Longhua Medical Scholar

Publisher

Springer Science and Business Media LLC

Subject

Complementary and alternative medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12906-019-2601-x.pdf

Reference27 articles.

1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.

2. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, De WM. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919.

3. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Jr CW, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2016;389(10066):299.

4. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017. https://doi.org/10.1016/S1470-2045(17)30608-3 .

5. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of inflammatory response-related molecular mechanisms based on the ATM/ATR/p53 pathway in tumor cells;Computers in Biology and Medicine;2024-09

2. Treating cancer through modulating exosomal protein loading and function: The prospects of natural products and traditional Chinese medicine;Pharmacological Research;2024-05

3. Survival mechanisms of circulating tumor cells and their implications for cancer treatment;Cancer and Metastasis Reviews;2024-03-04

4. Jinfukang inhibits lung cancer metastasis by regulating T cell receptors;Journal of Ethnopharmacology;2024-01

5. Evaluation of Antioxidant and Oxidative Stress Activity of Carthamus tinctorius L. Extract in Lung Cancer A549 Cells;Indian Journal of Pharmaceutical Education and Research;2023-10-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3